Concentration and pH dependent aggregation of hydrophobic drug molecules and relevance to oral bioavailability

被引:116
作者
Frenkel, YV
Clark, AD
Das, K
Wang, YH
Lewi, PJ
Janssen, PAJ
Arnold, E
机构
[1] Rutgers State Univ, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA
[2] Rutgers State Univ, Dept Chem & Biol Chem, Piscataway, NJ 08854 USA
[3] Univ Med & Dent New Jersey, Dept Biochem & Mol Biol, Piscataway, NJ 08854 USA
[4] Janssen Pharmaceut NV, Ctr Mol Design, B-2350 Vosselaar, Belgium
关键词
D O I
10.1021/jm049439i
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
We have examined selected physicochemical properties of compounds from the diaryltriazine/diarylpyrimidine (DATA/DAPY) classes of non-nucleoside reverse transcriptase inhibitors (NNRTIs) and explored possible correlations with their bioavailability. In simple aqueous solutions designed to mimic the gastrointestinal (GI) environment of a fasting individual, all NNRTIs demonstrated formation of aggregates as detected by dynamic light scattering and electron microscopy. Under various conditions mimicking physiological transitions in the GI environment, aggregate size distributions were shown to depend on compound concentration and pH. NNRTIs with good absorption were capable of forming aggregates with hydrodynamic radii of <= 100 nm at higher concentrations and over wide ranges of pH, while poorly absorbed inhibitors form aggregates with radii of >= 250 nm at concentrations above 0.01 mM, probably representing precipitate. We propose a model in which the uptake rate into systemic circulation depends on having hydrophobic drug aggregates of appropriate size available for absorption at different locations within the GI tract.
引用
收藏
页码:1974 / 1983
页数:10
相关论文
共 54 条
[1]   Guidances related to bioavailability and bioequivalence: European industry perspective [J].
Ahr, G ;
Voith, B ;
Kuhlmann, J .
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2000, 25 (01) :25-27
[2]   A THEORETICAL BASIS FOR A BIOPHARMACEUTIC DRUG CLASSIFICATION - THE CORRELATION OF IN-VITRO DRUG PRODUCT DISSOLUTION AND IN-VIVO BIOAVAILABILITY [J].
AMIDON, GL ;
LENNERNAS, H ;
SHAH, VP ;
CRISON, JR .
PHARMACEUTICAL RESEARCH, 1995, 12 (03) :413-420
[3]   TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1 [J].
Andries, K ;
Azijn, H ;
Thielemans, T ;
Ludovici, D ;
Kukla, M ;
Heeres, J ;
Janssen, P ;
De Corte, B ;
Vingerhoets, J ;
Pauwels, R ;
de Béthune, MP .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (12) :4680-4686
[4]   High-throughput screening for stability and inhibitory activity of compounds toward cytochrome P450-mediated metabolism [J].
Ansede, JH ;
Thakker, DR .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2004, 93 (02) :239-255
[5]  
Caldwell GW, 1998, J MASS SPECTROM, V33, P607, DOI 10.1002/(SICI)1096-9888(199807)33:7<607::AID-JMS672>3.0.CO
[6]  
2-O
[7]   HUMAN GASTRIC-EMPTYING AND COLONIC FILLING OF SOLIDS CHARACTERIZED BY A NEW METHOD [J].
CAMILLERI, M ;
COLEMONT, LJ ;
PHILLIPS, SF ;
BROWN, ML ;
THOMFORDE, GM ;
CHAPMAN, N ;
ZINSMEISTER, AR .
AMERICAN JOURNAL OF PHYSIOLOGY, 1989, 257 (02) :G284-G290
[8]  
Charman WN., 1992, LYMPHATIC TRANSPORT
[9]   ESTIMATING THE MAXIMAL POTENTIAL FOR INTESTINAL LYMPHATIC TRANSPORT OF LIPOPHILIC DRUG MOLECULES [J].
CHARMAN, WNA ;
STELLA, VJ .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1986, 34 (1-2) :175-178
[10]   Oral particulate delivery: status and future trends [J].
Chen, HM ;
Langer, R .
ADVANCED DRUG DELIVERY REVIEWS, 1998, 34 (2-3) :339-350